Parental longevity and survival among patients with multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study.

• Published in: British Journal of Haematology
• Main Authors: Sverrisdóttir, Ingigerður S, Lund, Sigrún H, Turesson, Ingemar, Björkholm, Magnus, Goldin, Lynn R, Landgren, Ola, Kristinsson, Sigurður Y
• Other Authors: 1 Landspítali, National University Hospital, Reykjavík, Iceland. 2 Faculty of Medicine, University of Iceland, Reykjavík, Iceland. 3 Skåne, University Hospital Malmö, Malmö, Sweden. 4 Department of Medicine, Division of Haematology, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden. 5 Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. 6 Myeloma Service, Division of Hematology Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. 7 Department of Haematology, Landspitali, National University Hospital, Reykjavik, Iceland.
• Format: Article in Journal/Newspaper
• Language: English
• Published: Wiley 2019
• Subjects: MGUS; longevity; multiple myeloma; survival; Mergæxli; Lífslíkur; Langlífi; Foreldrar; Parents; Iceland
• Online Access: http://hdl.handle.net/2336/621031; https://doi.org/10.1111/bjh.15883

Parental longevity is associated with an increased life expectancy; results with regard to specific diseases are conflicting. There are limited data focusing on host characteristics and their effect on survival among multiple myeloma (MM) patients and individuals with monoclonal gammopathy of undetermined significance (MGUS). Therefore, our aim was to evaluate the impact of parental longevity on survival of patients with MM and MGUS. A total of 4675 patients with MM, 6812 MGUS patients and 13 398 population-based controls for MM as well as 19 110 controls for MGUS, from 1988 to 2013, were included in the study. Longevity was defined as >90 years of age. Among MM patients, parental longevity was associated with a decreased risk of death [hazard ratio (HR) = 0·92, 95% confidence interval (CI) 0·84-0·99] and the same was true for MGUS patients (HR = 0·87, 95% CI 0·78-0·96). Having one long lived parent significantly decreased the risk of death in both groups, but was not statistically significant when both parents exceeded 90 years of age. In conclusion, parental longevity decreases the risk of death for patients with MM and MGUS which may reflect the importance of the host's genetic and environmental factors in relation to survival. Swedish Blodcancerfonden Swedish Cancer Society Stockholm County Council Karolinska Institutet Karolinska Institutet Foundation University of Iceland Research Fund Icelandic Centre for Research (RANNIS) Landspitali University Hospital Research Fund Memorial Sloan Kettering Core Grant from the National Institutes of Health, National Cancer Institute